Physician profile
Eric Dewayne Davis
NPI 1598052094
$10,102.09
in general payments reported to CMS, 2019-2025
39 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $706 · 2021: $1,747 · 2022: $1,626 · 2023: $1,700 · 2024: $1,817 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,525 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,524.69 |
| Education | $112.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,839.68 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $1,017.86 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $745.04 | 2019-2025 | Entyvio, Gattex |
| Daiichi Sankyo INC. | $631.04 | 2020-2024 | Injectafer |
| Braintree Laboratories, INC. | $345.20 | 2019-2025 | Sutab, Suflave |
| Ardelyx, INC. | $343.48 | 2022-2024 | Ibsrela |
| Pfizer INC. | $319.77 | 2019-2025 | |
| Genzyme Corporation | $315.76 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.83 | 2019-2024 | Trulance, Xifaxan |
| Qol Medical, LLC | $303.57 | 2022-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $272.77 | 2020-2022 | |
| Boston Scientific Corporation | $263.96 | 2020-2025 | Resolution 360 Clip |
| Regeneron Healthcare Solutions, INC. | $233.45 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $218.91 | 2019-2021 | |
| Vivus LLC | $209.76 | 2021-2025 | Qsymia, Pancreaze |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $195.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $183.07 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $156.51 | 2019-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $153.42 | 2019-2022 | |
| Romark Laboratories, Lc | $144.17 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $107.80 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $91.54 | 2024-2025 | Omvoh |
| Amgen INC. | $83.91 | 2020-2021 | |
| Celgene Corporation | $69.07 | 2021-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $68.10 | 2024 | |
| Evoke Pharma, INC. | $60.40 | 2021-2025 | |
| Allergan, INC. | $59.73 | 2019-2020 | |
| Organon LLC | $57.79 | 2023-2024 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $46.42 | 2023 | |
| Celltrion USA INC. | $44.15 | 2024-2025 | Vegzelma, Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.60 | 2023 | Cyltezo |
| Avanos Medical | $38.00 | 2024-2025 | Standard Rf Disposables |
| Merck Sharp & Dohme LLC | $26.50 | 2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $22.33 | 2025 | Iqirvo |
| Ethicon US, LLC | $20.26 | 2022 | |
| Ucb, INC. | $16.32 | 2021 | |
| Exact Sciences Corporation | $15.76 | 2023 | Cologuard Collection Kit |
| Trevena, INC. | $15.69 | 2021 | |
| Shionogi INC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.